ArticleFrontiers in oncology2022

Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trial.

Katya Galactionova et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.